SOPHiA GENETICS S.A.

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, GEHC has a market cap of 31.4B. Regarding current trading prices, SOPH is priced at $4.85, while GEHC trades at $68.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas GEHC's P/E ratio is 15.13. In terms of profitability, SOPH's ROE is -1.17%, compared to GEHC's ROE of +0.17%. Regarding short-term risk, SOPH is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check GEHC's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, BTSGU has a market cap of 31B. Regarding current trading prices, SOPH is priced at $4.85, while BTSGU trades at $159.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas BTSGU's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to BTSGU's ROE of +0.11%. Regarding short-term risk, SOPH is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check BTSGU's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, VEEV has a market cap of 26.5B. Regarding current trading prices, SOPH is priced at $4.85, while VEEV trades at $161.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas VEEV's P/E ratio is 29.62. In terms of profitability, SOPH's ROE is -1.17%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, SOPH is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check VEEV's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, SOPH is priced at $4.85, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas GEHCV's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to GEHCV's ROE of +0.21%. Regarding short-term risk, SOPH is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check GEHCV's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, BTSG has a market cap of 9.3B. Regarding current trading prices, SOPH is priced at $4.85, while BTSG trades at $48.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas BTSG's P/E ratio is 100.33. In terms of profitability, SOPH's ROE is -1.17%, compared to BTSG's ROE of +0.11%. Regarding short-term risk, SOPH is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check BTSG's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, TEM has a market cap of 9.1B. Regarding current trading prices, SOPH is priced at $4.85, while TEM trades at $52.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas TEM's P/E ratio is -36.96. In terms of profitability, SOPH's ROE is -1.17%, compared to TEM's ROE of -0.60%. Regarding short-term risk, SOPH is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check TEM's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, SOPH is priced at $4.85, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas SGFY's P/E ratio is 70.91. In terms of profitability, SOPH's ROE is -1.17%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, SOPH is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SGFY's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, HQY has a market cap of 7B. Regarding current trading prices, SOPH is priced at $4.85, while HQY trades at $82.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas HQY's P/E ratio is 33.52. In terms of profitability, SOPH's ROE is -1.17%, compared to HQY's ROE of +0.10%. Regarding short-term risk, SOPH is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check HQY's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, SOPH is priced at $4.85, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas RCM's P/E ratio is -102.21. In terms of profitability, SOPH's ROE is -1.17%, compared to RCM's ROE of +0.00%. Regarding short-term risk, SOPH is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check RCM's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, DOCS has a market cap of 4.5B. Regarding current trading prices, SOPH is priced at $4.85, while DOCS trades at $24.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas DOCS's P/E ratio is 20.17. In terms of profitability, SOPH's ROE is -1.17%, compared to DOCS's ROE of +0.23%. Regarding short-term risk, SOPH is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check DOCS's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, HNGE has a market cap of 3.5B. Regarding current trading prices, SOPH is priced at $4.85, while HNGE trades at $44.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas HNGE's P/E ratio is -5.70. In terms of profitability, SOPH's ROE is -1.17%, compared to HNGE's ROE of -1.32%. Regarding short-term risk, SOPH is more volatile compared to HNGE. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check HNGE's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, SOPH is priced at $4.85, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas ONEM's P/E ratio is -7.77. In terms of profitability, SOPH's ROE is -1.17%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, SOPH is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check ONEM's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, PRVA has a market cap of 3B. Regarding current trading prices, SOPH is priced at $4.85, while PRVA trades at $23.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas PRVA's P/E ratio is 132.44. In terms of profitability, SOPH's ROE is -1.17%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, SOPH is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check PRVA's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, TXG has a market cap of 2.8B. Regarding current trading prices, SOPH is priced at $4.85, while TXG trades at $22.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas TXG's P/E ratio is -63.09. In terms of profitability, SOPH's ROE is -1.17%, compared to TXG's ROE of -0.06%. Regarding short-term risk, SOPH is more volatile compared to TXG. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check TXG's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, HTFL has a market cap of 2.6B. Regarding current trading prices, SOPH is priced at $4.85, while HTFL trades at $30.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas HTFL's P/E ratio is -9.60. In terms of profitability, SOPH's ROE is -1.17%, compared to HTFL's ROE of +0.38%. Regarding short-term risk, SOPH is more volatile compared to HTFL. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check HTFL's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, SOPH is priced at $4.85, while PINC trades at $28.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas PINC's P/E ratio is 166.24. In terms of profitability, SOPH's ROE is -1.17%, compared to PINC's ROE of -0.02%. Regarding short-term risk, SOPH is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check PINC's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, WGS has a market cap of 2B. Regarding current trading prices, SOPH is priced at $4.85, while WGS trades at $68.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas WGS's P/E ratio is -93.88. In terms of profitability, SOPH's ROE is -1.17%, compared to WGS's ROE of -0.07%. Regarding short-term risk, SOPH is more volatile compared to WGS. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check WGS's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, OMCL has a market cap of 1.7B. Regarding current trading prices, SOPH is priced at $4.85, while OMCL trades at $37.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas OMCL's P/E ratio is 934.25. In terms of profitability, SOPH's ROE is -1.17%, compared to OMCL's ROE of +0.00%. Regarding short-term risk, SOPH is more volatile compared to OMCL. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check OMCL's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, SOPH is priced at $4.85, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas NXGN's P/E ratio is -266.00. In terms of profitability, SOPH's ROE is -1.17%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, SOPH is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check NXGN's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, PGNY has a market cap of 1.5B. Regarding current trading prices, SOPH is priced at $4.85, while PGNY trades at $18.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas PGNY's P/E ratio is 27.95. In terms of profitability, SOPH's ROE is -1.17%, compared to PGNY's ROE of +0.11%. Regarding short-term risk, SOPH is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check PGNY's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, SOPH is priced at $4.85, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas AGTI's P/E ratio is -71.79. In terms of profitability, SOPH's ROE is -1.17%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, SOPH is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check AGTI's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, TDOC has a market cap of 1B. Regarding current trading prices, SOPH is priced at $4.85, while TDOC trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas TDOC's P/E ratio is -0.17. In terms of profitability, SOPH's ROE is -1.17%, compared to TDOC's ROE of -0.14%. Regarding short-term risk, SOPH is more volatile compared to TDOC. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check TDOC's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, CERT has a market cap of 1B. Regarding current trading prices, SOPH is priced at $4.85, while CERT trades at $6.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas CERT's P/E ratio is -632.00. In terms of profitability, SOPH's ROE is -1.17%, compared to CERT's ROE of -0.00%. Regarding short-term risk, SOPH is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CERT's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, SDGR has a market cap of 870.4M. Regarding current trading prices, SOPH is priced at $4.85, while SDGR trades at $11.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas SDGR's P/E ratio is -8.36. In terms of profitability, SOPH's ROE is -1.17%, compared to SDGR's ROE of -0.29%. Regarding short-term risk, SOPH is more volatile compared to SDGR. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SDGR's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, CCLDO has a market cap of 855.7M. Regarding current trading prices, SOPH is priced at $4.85, while CCLDO trades at $27.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas CCLDO's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to CCLDO's ROE of +0.19%. Regarding short-term risk, SOPH is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CCLDO's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, OMDA has a market cap of 844.4M. Regarding current trading prices, SOPH is priced at $4.85, while OMDA trades at $14.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas OMDA's P/E ratio is -40.94. In terms of profitability, SOPH's ROE is -1.17%, compared to OMDA's ROE of -0.07%. Regarding short-term risk, SOPH is more volatile compared to OMDA. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check OMDA's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, GDRX has a market cap of 791.6M. Regarding current trading prices, SOPH is priced at $4.85, while GDRX trades at $2.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas GDRX's P/E ratio is 25.67. In terms of profitability, SOPH's ROE is -1.17%, compared to GDRX's ROE of +0.05%. Regarding short-term risk, SOPH is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check GDRX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, NUTX has a market cap of 644.5M. Regarding current trading prices, SOPH is priced at $4.85, while NUTX trades at $108.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas NUTX's P/E ratio is 10.33. In terms of profitability, SOPH's ROE is -1.17%, compared to NUTX's ROE of +0.24%. Regarding short-term risk, SOPH is more volatile compared to NUTX. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check NUTX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, SOPH is priced at $4.85, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to MPLN-WT's ROE of +3.78%. Regarding short-term risk, SOPH is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MPLN-WT's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, HSTM has a market cap of 624.5M. Regarding current trading prices, SOPH is priced at $4.85, while HSTM trades at $21.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas HSTM's P/E ratio is 34.93. In terms of profitability, SOPH's ROE is -1.17%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, SOPH is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check HSTM's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, PHR has a market cap of 579.4M. Regarding current trading prices, SOPH is priced at $4.85, while PHR trades at $9.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas PHR's P/E ratio is 238.38. In terms of profitability, SOPH's ROE is -1.17%, compared to PHR's ROE of +0.01%. Regarding short-term risk, SOPH is less volatile compared to PHR. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check PHR's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, SOPH is priced at $4.85, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas ACCD's P/E ratio is -3.08. In terms of profitability, SOPH's ROE is -1.17%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, SOPH is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check ACCD's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, SOPH is priced at $4.85, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas SHCR's P/E ratio is -3.76. In terms of profitability, SOPH's ROE is -1.17%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, SOPH is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SHCR's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, CTEV has a market cap of 405M. Regarding current trading prices, SOPH is priced at $4.85, while CTEV trades at $23.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas CTEV's P/E ratio is -1.38. In terms of profitability, SOPH's ROE is -1.17%, compared to CTEV's ROE of +3.78%. Regarding short-term risk, SOPH is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check CTEV's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, SOPH is priced at $4.85, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas SLGC's P/E ratio is -3.04. In terms of profitability, SOPH's ROE is -1.17%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, SOPH is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SLGC's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, SOPH is priced at $4.85, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, SOPH's ROE is -1.17%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, SOPH is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SLGCW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, NRC has a market cap of 391.9M. Regarding current trading prices, SOPH is priced at $4.85, while NRC trades at $17.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas NRC's P/E ratio is 34.46. In terms of profitability, SOPH's ROE is -1.17%, compared to NRC's ROE of +0.59%. Regarding short-term risk, SOPH is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check NRC's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, TBRG has a market cap of 386.8M. Regarding current trading prices, SOPH is priced at $4.85, while TBRG trades at $25.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas TBRG's P/E ratio is 88.86. In terms of profitability, SOPH's ROE is -1.17%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, SOPH is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check TBRG's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, SOPH is priced at $4.85, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas MPLN's P/E ratio is -0.23. In terms of profitability, SOPH's ROE is -1.17%, compared to MPLN's ROE of +3.78%. Regarding short-term risk, SOPH is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MPLN's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, SY has a market cap of 357.9M. Regarding current trading prices, SOPH is priced at $4.85, while SY trades at $2.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas SY's P/E ratio is -7.77. In terms of profitability, SOPH's ROE is -1.17%, compared to SY's ROE of -0.14%. Regarding short-term risk, SOPH is more volatile compared to SY. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SY's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, EVH has a market cap of 348.3M. Regarding current trading prices, SOPH is priced at $4.85, while EVH trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas EVH's P/E ratio is -0.62. In terms of profitability, SOPH's ROE is -1.17%, compared to EVH's ROE of -0.69%. Regarding short-term risk, SOPH is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check EVH's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, SLP has a market cap of 294.2M. Regarding current trading prices, SOPH is priced at $4.85, while SLP trades at $14.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas SLP's P/E ratio is -4.67. In terms of profitability, SOPH's ROE is -1.17%, compared to SLP's ROE of -0.49%. Regarding short-term risk, SOPH is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SLP's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, SOPH is priced at $4.85, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas TRHC's P/E ratio is -4.27. In terms of profitability, SOPH's ROE is -1.17%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, SOPH is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check TRHC's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, CARL has a market cap of 272.9M. Regarding current trading prices, SOPH is priced at $4.85, while CARL trades at $10.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas CARL's P/E ratio is -4.82. In terms of profitability, SOPH's ROE is -1.17%, compared to CARL's ROE of -2.64%. Regarding short-term risk, SOPH is more volatile compared to CARL. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CARL's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, SOPH is priced at $4.85, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas SMFR's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to SMFR's ROE of -0.07%. Regarding short-term risk, SOPH is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SMFR's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, SPOK has a market cap of 235.7M. Regarding current trading prices, SOPH is priced at $4.85, while SPOK trades at $11.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas SPOK's P/E ratio is 15.16. In terms of profitability, SOPH's ROE is -1.17%, compared to SPOK's ROE of +0.11%. Regarding short-term risk, SOPH is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SPOK's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, SOPH is priced at $4.85, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas CPSI's P/E ratio is -183.80. In terms of profitability, SOPH's ROE is -1.17%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, SOPH is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check CPSI's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, CCLD has a market cap of 129.6M. Regarding current trading prices, SOPH is priced at $4.85, while CCLD trades at $3.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas CCLD's P/E ratio is 30.50. In terms of profitability, SOPH's ROE is -1.17%, compared to CCLD's ROE of +0.19%. Regarding short-term risk, SOPH is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CCLD's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, OPRX has a market cap of 120.6M. Regarding current trading prices, SOPH is priced at $4.85, while OPRX trades at $6.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas OPRX's P/E ratio is 23.81. In terms of profitability, SOPH's ROE is -1.17%, compared to OPRX's ROE of +0.04%. Regarding short-term risk, SOPH is more volatile compared to OPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check OPRX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, SOPH is priced at $4.85, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas AUGX's P/E ratio is -4.99. In terms of profitability, SOPH's ROE is -1.17%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, SOPH is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check AUGX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, DH has a market cap of 106.6M. Regarding current trading prices, SOPH is priced at $4.85, while DH trades at $1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas DH's P/E ratio is -0.78. In terms of profitability, SOPH's ROE is -1.17%, compared to DH's ROE of -0.47%. Regarding short-term risk, SOPH is more volatile compared to DH. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check DH's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, HCAT has a market cap of 101.5M. Regarding current trading prices, SOPH is priced at $4.85, while HCAT trades at $1.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas HCAT's P/E ratio is -0.54. In terms of profitability, SOPH's ROE is -1.17%, compared to HCAT's ROE of -0.55%. Regarding short-term risk, SOPH is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check HCAT's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, AMWL has a market cap of 98.2M. Regarding current trading prices, SOPH is priced at $4.85, while AMWL trades at $5.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas AMWL's P/E ratio is -0.99. In terms of profitability, SOPH's ROE is -1.17%, compared to AMWL's ROE of -0.36%. Regarding short-term risk, SOPH is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check AMWL's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, FORA has a market cap of 67.3M. Regarding current trading prices, SOPH is priced at $4.85, while FORA trades at $2.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas FORA's P/E ratio is -23.94. In terms of profitability, SOPH's ROE is -1.17%, compared to FORA's ROE of -0.09%. Regarding short-term risk, SOPH is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check FORA's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, SOPH is priced at $4.85, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas CCLDP's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to CCLDP's ROE of +0.19%. Regarding short-term risk, SOPH is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CCLDP's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, ONMD has a market cap of 36.1M. Regarding current trading prices, SOPH is priced at $4.85, while ONMD trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas ONMD's P/E ratio is -18.33. In terms of profitability, SOPH's ROE is -1.17%, compared to ONMD's ROE of +0.41%. Regarding short-term risk, SOPH is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check ONMD's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, SOPH is priced at $4.85, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas SNCE's P/E ratio is -0.27. In terms of profitability, SOPH's ROE is -1.17%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, SOPH is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SNCE's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, SOPH is priced at $4.85, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas AKLI's P/E ratio is -0.71. In terms of profitability, SOPH's ROE is -1.17%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, SOPH is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check AKLI's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, SOPH is priced at $4.85, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas SHLT's P/E ratio is -3.87. In terms of profitability, SOPH's ROE is -1.17%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, SOPH is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SHLT's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, SOPH is priced at $4.85, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -1.17%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, SOPH is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SHCRW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, BEAT has a market cap of 31.1M. Regarding current trading prices, SOPH is priced at $4.85, while BEAT trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas BEAT's P/E ratio is -1.46. In terms of profitability, SOPH's ROE is -1.17%, compared to BEAT's ROE of -5.71%. Regarding short-term risk, SOPH is more volatile compared to BEAT. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check BEAT's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, SOPH is priced at $4.85, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas STRM's P/E ratio is -2.40. In terms of profitability, SOPH's ROE is -1.17%, compared to STRM's ROE of -0.50%. Regarding short-term risk, SOPH is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check STRM's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, SOPH is priced at $4.85, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas RNLX's P/E ratio is -0.33. In terms of profitability, SOPH's ROE is -1.17%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, SOPH is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check RNLX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, SOPH is priced at $4.85, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas LIFW's P/E ratio is -0.02. In terms of profitability, SOPH's ROE is -1.17%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, SOPH is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check LIFW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, EUDA has a market cap of 20.1M. Regarding current trading prices, SOPH is priced at $4.85, while EUDA trades at $10.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas EUDA's P/E ratio is 26.55. In terms of profitability, SOPH's ROE is -1.17%, compared to EUDA's ROE of +0.14%. Regarding short-term risk, SOPH is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check EUDA's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, SOPH is priced at $4.85, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas BBLN's P/E ratio is -0.04. In terms of profitability, SOPH's ROE is -1.17%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, SOPH is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check BBLN's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, SOPH is priced at $4.85, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas ETAO's P/E ratio is -0.01. In terms of profitability, SOPH's ROE is -1.17%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, SOPH is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check ETAO's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, BFRG has a market cap of 8.6M. Regarding current trading prices, SOPH is priced at $4.85, while BFRG trades at $0.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas BFRG's P/E ratio is -1.29. In terms of profitability, SOPH's ROE is -1.17%, compared to BFRG's ROE of -2.73%. Regarding short-term risk, SOPH is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check BFRG's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, SOPH is priced at $4.85, while HLTH trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas HLTH's P/E ratio is -0.02. In terms of profitability, SOPH's ROE is -1.17%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, SOPH is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check HLTH's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, ZCMD has a market cap of 6.8M. Regarding current trading prices, SOPH is priced at $4.85, while ZCMD trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas ZCMD's P/E ratio is -1.14. In terms of profitability, SOPH's ROE is -1.17%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, SOPH is more volatile compared to ZCMD. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check ZCMD's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, SCNX has a market cap of 6.3M. Regarding current trading prices, SOPH is priced at $4.85, while SCNX trades at $0.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas SCNX's P/E ratio is -0.15. In terms of profitability, SOPH's ROE is -1.17%, compared to SCNX's ROE of -2.36%. Regarding short-term risk, SOPH is more volatile compared to SCNX. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SCNX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, SOPH is priced at $4.85, while UPH-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, SOPH is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check UPH-WT's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, SOPH is priced at $4.85, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas UPH's P/E ratio is -0.07. In terms of profitability, SOPH's ROE is -1.17%, compared to UPH's ROE of -1.05%. Regarding short-term risk, SOPH is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check UPH's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, MGRX has a market cap of 4.4M. Regarding current trading prices, SOPH is priced at $4.85, while MGRX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas MGRX's P/E ratio is -0.20. In terms of profitability, SOPH's ROE is -1.17%, compared to MGRX's ROE of -1.17%. Regarding short-term risk, SOPH is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MGRX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, SOPH is priced at $4.85, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas PEARW's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -1.17%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, SOPH is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check PEARW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, SOPH is priced at $4.85, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas PEAR's P/E ratio is -0.08. In terms of profitability, SOPH's ROE is -1.17%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, SOPH is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check PEAR's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, VSEE has a market cap of 3.5M. Regarding current trading prices, SOPH is priced at $4.85, while VSEE trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas VSEE's P/E ratio is -0.29. In terms of profitability, SOPH's ROE is -1.17%, compared to VSEE's ROE of +6.29%. Regarding short-term risk, SOPH is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check VSEE's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, BEATW has a market cap of 3.3M. Regarding current trading prices, SOPH is priced at $4.85, while BEATW trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas BEATW's P/E ratio is -0.20. In terms of profitability, SOPH's ROE is -1.17%, compared to BEATW's ROE of -5.71%. Regarding short-term risk, SOPH is more volatile compared to BEATW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check BEATW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, BFRGW has a market cap of 2.6M. Regarding current trading prices, SOPH is priced at $4.85, while BFRGW trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas BFRGW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to BFRGW's ROE of -2.73%. Regarding short-term risk, SOPH is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check BFRGW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, HCTI has a market cap of 2.5M. Regarding current trading prices, SOPH is priced at $4.85, while HCTI trades at $2.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas HCTI's P/E ratio is -0.01. In terms of profitability, SOPH's ROE is -1.17%, compared to HCTI's ROE of -1.01%. Regarding short-term risk, SOPH is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check HCTI's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, SOPH is priced at $4.85, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas OTRK's P/E ratio is -0.02. In terms of profitability, SOPH's ROE is -1.17%, compared to OTRK's ROE of -1.66%. Regarding short-term risk, SOPH is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check OTRK's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, EUDAW has a market cap of 2.1M. Regarding current trading prices, SOPH is priced at $4.85, while EUDAW trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas EUDAW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to EUDAW's ROE of +0.14%. Regarding short-term risk, SOPH is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check EUDAW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, ACON has a market cap of 1.8M. Regarding current trading prices, SOPH is priced at $4.85, while ACON trades at $3.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas ACON's P/E ratio is -0.24. In terms of profitability, SOPH's ROE is -1.17%, compared to ACON's ROE of -0.00%. Regarding short-term risk, SOPH is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check ACON's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, SOPH is priced at $4.85, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas CMAX's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -1.17%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, SOPH is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CMAX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, VSEEW has a market cap of 1.3M. Regarding current trading prices, SOPH is priced at $4.85, while VSEEW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas VSEEW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to VSEEW's ROE of +6.29%. Regarding short-term risk, SOPH is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check VSEEW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, SOPH is priced at $4.85, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, SOPH is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check LIFWZ's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, MSPR has a market cap of 587.4K. Regarding current trading prices, SOPH is priced at $4.85, while MSPR trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas MSPR's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to MSPR's ROE of +3.93%. Regarding short-term risk, SOPH is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MSPR's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, SOPH is priced at $4.85, while MSPRZ trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, SOPH is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MSPRZ's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, WORX has a market cap of 303.5K. Regarding current trading prices, SOPH is priced at $4.85, while WORX trades at $1.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas WORX's P/E ratio is -0.12. In terms of profitability, SOPH's ROE is -1.17%, compared to WORX's ROE of -0.73%. Regarding short-term risk, SOPH is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check WORX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, WGSWW has a market cap of 171.9K. Regarding current trading prices, SOPH is priced at $4.85, while WGSWW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas WGSWW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to WGSWW's ROE of -0.07%. Regarding short-term risk, SOPH is more volatile compared to WGSWW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check WGSWW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, SOPH is priced at $4.85, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas KERN's P/E ratio is -0.01. In terms of profitability, SOPH's ROE is -1.17%, compared to KERN's ROE of -0.02%. Regarding short-term risk, SOPH is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check KERN's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, SOPH is priced at $4.85, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas KERNW's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -1.17%, compared to KERNW's ROE of -0.02%. Regarding short-term risk, SOPH is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check KERNW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, SOPH is priced at $4.85, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas LIFWW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, SOPH is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check LIFWW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, OTRKP has a market cap of 50.1K. Regarding current trading prices, SOPH is priced at $4.85, while OTRKP trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas OTRKP's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -1.17%, compared to OTRKP's ROE of -1.66%. Regarding short-term risk, SOPH is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check OTRKP's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, SOPH is priced at $4.85, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas CMAXW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, SOPH is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CMAXW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, ACONW has a market cap of 21.3K. Regarding current trading prices, SOPH is priced at $4.85, while ACONW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas ACONW's P/E ratio is -0.01. In terms of profitability, SOPH's ROE is -1.17%, compared to ACONW's ROE of -0.00%. Regarding short-term risk, SOPH is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check ACONW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, ICCT has a market cap of 5.4K. Regarding current trading prices, SOPH is priced at $4.85, while ICCT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas ICCT's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to ICCT's ROE of +11.65%. Regarding short-term risk, SOPH is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check ICCT's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, MSPRW has a market cap of 4.1K. Regarding current trading prices, SOPH is priced at $4.85, while MSPRW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas MSPRW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to MSPRW's ROE of +3.93%. Regarding short-term risk, SOPH is more volatile compared to MSPRW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check MSPRW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 347.6M. In comparison, FOXO has a market cap of 3K. Regarding current trading prices, SOPH is priced at $4.85, while FOXO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.22, whereas FOXO's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.17%, compared to FOXO's ROE of -0.91%. Regarding short-term risk, SOPH is less volatile compared to FOXO. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check FOXO's competition here